Experimental Oncology 2022 August [Link] D Endoh, K Ishii, K Kohno, N Virgona, Y Miyakoshi, T Yano, T Ishida Abstract Background: Hypoxia has been noted as a key factor for induction and maintenance of cancer stemness thereby leading to therapy resistance. Three-dimensional (3D) spheroid models demonstrate a heterogeneity of hypoxic regions replicating the in vivo…

Read More

Targeted Oncology 2022 July [Link] Fatéméh Dubois, Céline Bazille, Jérôme Levallet, Elodie Maille, Solenn Brosseau, Jeannick Madelaine, Emmanuel Bergot, Gérard Zalcman, Guénaëlle Levallet Abstract Malignant pleural mesothelioma is a rare and aggressive neoplasm, which has primarily been attributed to the exposure to asbestos fibers (83% of cases); yet, despite a ban of using asbestos in…

Read More

Targeted Oncology 2022 July 30 [Link] Fatéméh Dubois, Céline Bazille, Jérôme Levallet, Elodie Maille, Solenn Brosseau, Jeannick Madelaine, Emmanuel Bergot, Gérard Zalcman, Guénaëlle Levallet Abstract Malignant pleural mesothelioma is a rare and aggressive neoplasm, which has primarily been attributed to the exposure to asbestos fibers (83% of cases); yet, despite a ban of using asbestos…

Read More

World Journal of Surgical Oncology 2022 June 29 [Link]Jianting Ma, Shengzhi Zhang Abstract Background: Prognosis in malignant peritoneal mesothelioma (MPM) remains poor, and the associated factors are unclear. Therefore, this study aimed to investigate the prognostic factors of MPM. Methods: A total of 52 female MPM patients treated in 2012-2017 were retrospectively analyzed. Kaplan-Meier survival…

Read More

The Lancet Oncology 2022 May 16 [Link] Marjorie G Zauderer, Peter W Szlosarek, Sylvestre Le Moulec, Sanjay Popat, Paul Taylor, David Planchard, Arnaud Scherpereel, Marianna Koczywas, Martin Forster, Robert B Cameron, Tobias Peikert, Evren Kocabaş Argon, Neil R Michaud, Attila Szanto, Jay Yang, Yingxue Chen, Vikram Kansra, Shefali Agarwal, Dean A Fennell Abstract Background: Treatment…

Read More

Translational Lung Cancer Research 2022 April [Link] Rong Sun, Ryosuke Tanino, Xuexia Tong, Eshat Fahmida Haque, Yoshihiro Amano, Takeshi Isobe, Yukari Tsubata Abstract Background: Acquired pemetrexed resistance leads to treatment interruption in patients with malignant pleural mesothelioma (MPM). Insulin-like growth factor-I receptor (IGF-1R) inhibitor is a candidate for treating pemetrexed-naïve MPM. However, the efficacy of…

Read More

Journal of Thoracic Oncology 2022 April 27 [Link] Amber Louw, Vasiliki Panou, Weronika Maria Szejniuk, Christos Meristoudis, Siaw Ming Chai, Chris van Vliet, Y C Gary Lee, Ian M Dick, Tina Firth, Louise Andersen Lynggaard, Azadeh Birbaneh Asghari, Mogens Vyberg, Johnni Hansen, Jenette Creaney, Oluf Dimitri Røe Abstract Introduction: Pleural mesothelioma (PM) is an aggressive…

Read More

Virchows Archiv 2022 April 24 [Link] Francesca Napoli, Ida Rapa, Stefania Izzo, Angelica Rigutto, Roberta Libener, Chiara Riganti, Paolo Bironzo, Riccardo Taulli, Mauro Papotti, Marco Volante, Giorgio Scagliotti, Luisella Righi Abstract The standard front-line treatment for pleural mesothelioma (PM) is pemetrexed-based chemotherapy, whose major target is thymidylate synthase (TS). In several cancer models, miR-215 and…

Read More

Cancers 2022 April 16 [Link] Tugce Kutuk, Haley Appel, Maria Carolina Avendano, Federico Albrecht, Paul Kaywin, Suyen Ramos, Melanie E Suarez-Murias, Minesh P Mehta, Rupesh Kotecha Abstract Purpose: The objectives of this study were to evaluate the implementation, device usage rates, clinical outcomes, and treatment-related toxicities associated with TTFields and pemetrexed plus platinum-based chemotherapy in…

Read More

BMC Cancer 2022 April 20 [Link] Barbara Ziółkowska, Bożena Cybulska-Stopa, Dimitrios Papantoniou, Rafał Suwiński Abstract Background: Malignant pleural mesothelioma (MPM) is a rare, aggressive malignancy of the pleural cavity linked to asbestos exposure. The combination of pemetrexed and platinum is a standard first-line therapy for malignant pleural mesothelioma. Despite some progress, almost all MPM patients…

Read More